Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT(2A) receptor occupancy in schizophrenic patients

American Journal of Psychiatry

Volumn 156, Issue 6, 1999, Pages 869-875

  Nyberg, Svante ^a   Eriksson, Bo ^b   Oxenstierna, Gabriella ^b   Halldin, Christer ^b   Farde, Lars ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLSPIPERONE; CARBON 11; DOPAMINE 2 RECEPTOR; RACLOPRIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

EID: 0033014402     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.6.869     Document Type: Article

References (34)

1. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-392
2. Casey DE: Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 1989; 25:457-459
3. Gerlach J: New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991; 17:289-309
4. 2 antagonistic properties. J Pharmacol Exp Ther 1988; 244:685-693
5. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247:661-670
6. Schotte A, Janssen PMF, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs - in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124:57-73
7. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, doubleblind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712-726
8. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
9. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
10. Nyberg S, Nordström A-L, Halldin C, Farde L: Positron emission tomography studies on D2 dopamine receptor occupancy and antipsychotic drug plasma levels in man. Int Clin Psychopharmacol 1995; 10(suppl 3):81-85
11. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
12. Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99(suppl):S18-S27
13. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology (Berl) 1993; 110:265-272
14. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S: The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57:103-107
15. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1995; 117:55-61
16. 2 receptor binding in risperidone-treated patients. J Clin Psychopharmacol 1995; 15(suppl 1):19S-23S
17. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
18. von Knorring L, Lindström E: The Swedish version of the Positive and Negative Syndrome Scale for schizophrenia. Acta Psychiatr Scand 1992; 86:463-468
19. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
20. Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7:233
21. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
22. Huang M-L, Van Peer A, Woestenborghs RJ, De Coster R, Heykants JJ, Janssen AAI, Zylicz Z, Visscher HW, Jonkman JHG: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257-268
23. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O: A comparative PET study of five carbon-11 or fluorine-18 labeled salicylamides: preparation and in vitro dopamine D-2 binding. Int J Rad Appl Instrum B 1991; 18:871-881
24. Nyberg S, Farde L, Halldin C: A PET study of 5HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16:1-7
25. Litton JE, Holte S, Eriksson L: Evaluation of the Karolinska new positron camera system; the Scanditronix PC2048-15B. IEEE Trans Nucl Sci 1990; 37:743-748
26. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss W: The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994; 18:110-118
27. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989; 9:696-708
28. Andrée B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L: Positron emission tomographic analysis of dose-dependent MDL 100, 907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J Clin Pharmacol 1998; 18:317-323
29. 1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology (Berl) 1995; 119:1-8
30. 11C]raclopride binding in healthy young adults and schizophrenic patients - reliability and age effects. Hum Psychopharmacol 1992; 7:157-165
31. Nyberg S, Farde L, Halldin C: Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy: a PET study in haloperidol-treated patients. Psychiatry Res 1996; 67:163-171
32. Aravagiri M, Marder SR, Wirshing D, Wirshing WC: Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998; 31:102-109
33. Nyberg S, Farde L: The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed: commentary on "Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia." J Psychopharmacol 1997; 11:15-16
34. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154:799-804